JP2014177455A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014177455A5 JP2014177455A5 JP2014043175A JP2014043175A JP2014177455A5 JP 2014177455 A5 JP2014177455 A5 JP 2014177455A5 JP 2014043175 A JP2014043175 A JP 2014043175A JP 2014043175 A JP2014043175 A JP 2014043175A JP 2014177455 A5 JP2014177455 A5 JP 2014177455A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- kit
- cda
- substrate drug
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102100026846 Cytidine deaminase Human genes 0.000 claims 13
- 108010031325 Cytidine deaminase Proteins 0.000 claims 13
- 150000001875 compounds Chemical class 0.000 claims 12
- 229940079593 drug Drugs 0.000 claims 8
- 239000003814 drug Substances 0.000 claims 8
- 239000000758 substrate Substances 0.000 claims 8
- 239000008194 pharmaceutical composition Substances 0.000 claims 6
- 230000002401 inhibitory effect Effects 0.000 claims 3
- NMUSYJAQQFHJEW-UHFFFAOYSA-N 5-Azacytidine Natural products O=C1N=C(N)N=CN1C1C(O)C(O)C(CO)O1 NMUSYJAQQFHJEW-UHFFFAOYSA-N 0.000 claims 2
- XAUDJQYHKZQPEU-KVQBGUIXSA-N 5-aza-2'-deoxycytidine Chemical compound O=C1N=C(N)N=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 XAUDJQYHKZQPEU-KVQBGUIXSA-N 0.000 claims 2
- NMUSYJAQQFHJEW-KVTDHHQDSA-N 5-azacytidine Chemical compound O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-KVTDHHQDSA-N 0.000 claims 2
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 claims 2
- 229960002756 azacitidine Drugs 0.000 claims 2
- 230000015556 catabolic process Effects 0.000 claims 2
- 229960003603 decitabine Drugs 0.000 claims 2
- 238000006731 degradation reaction Methods 0.000 claims 2
- 239000002552 dosage form Substances 0.000 claims 2
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims 2
- 229960005277 gemcitabine Drugs 0.000 claims 2
- GVOISEJVFFIGQE-YCZSINBZSA-N n-[(1r,2s,5r)-5-[methyl(propan-2-yl)amino]-2-[(3s)-2-oxo-3-[[6-(trifluoromethyl)quinazolin-4-yl]amino]pyrrolidin-1-yl]cyclohexyl]acetamide Chemical compound CC(=O)N[C@@H]1C[C@H](N(C)C(C)C)CC[C@@H]1N1C(=O)[C@@H](NC=2C3=CC(=CC=C3N=CN=2)C(F)(F)F)CC1 GVOISEJVFFIGQE-YCZSINBZSA-N 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- AZYOZBIYZJGKSO-XKBRQERYSA-N 4-amino-1-[(2r,4s,5s)-5-[fluoro(hydroxy)methyl]-4-hydroxyoxolan-2-yl]pyrimidin-2-one Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](C(O)F)[C@@H](O)C1 AZYOZBIYZJGKSO-XKBRQERYSA-N 0.000 claims 1
- NGGRGTWYSXYVDK-RRKCRQDMSA-N 4-amino-5-chloro-1-[(2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one Chemical compound C1=C(Cl)C(N)=NC(=O)N1[C@@H]1O[C@H](CO)[C@@H](O)C1 NGGRGTWYSXYVDK-RRKCRQDMSA-N 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 125000001153 fluoro group Chemical group F* 0.000 claims 1
- GFFXZLZWLOBBLO-ASKVSEFXSA-N tezacitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(=C/F)/[C@H](O)[C@@H](CO)O1 GFFXZLZWLOBBLO-ASKVSEFXSA-N 0.000 claims 1
- 229950006410 tezacitabine Drugs 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US98039707P | 2007-10-16 | 2007-10-16 | |
| US60/980,397 | 2007-10-16 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010530110A Division JP5496899B2 (ja) | 2007-10-16 | 2008-10-16 | シチジンデアミナーゼ阻害剤としての２’−フルオロ−２’−デオキシテトラヒドロウリジン |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014177455A JP2014177455A (ja) | 2014-09-25 |
| JP2014177455A5 true JP2014177455A5 (enExample) | 2015-02-05 |
| JP5859588B2 JP5859588B2 (ja) | 2016-02-10 |
Family
ID=40251685
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010530110A Active JP5496899B2 (ja) | 2007-10-16 | 2008-10-16 | シチジンデアミナーゼ阻害剤としての２’−フルオロ−２’−デオキシテトラヒドロウリジン |
| JP2014043175A Active JP5859588B2 (ja) | 2007-10-16 | 2014-03-05 | シチジンデアミナーゼ阻害剤としての２’−フルオロ−２’−デオキシテトラヒドロウリジン |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010530110A Active JP5496899B2 (ja) | 2007-10-16 | 2008-10-16 | シチジンデアミナーゼ阻害剤としての２’−フルオロ−２’−デオキシテトラヒドロウリジン |
Country Status (39)
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8404716B2 (en) | 2002-10-15 | 2013-03-26 | Celgene Corporation | Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine |
| US11116782B2 (en) | 2002-10-15 | 2021-09-14 | Celgene Corporation | Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine |
| US7964580B2 (en) | 2007-03-30 | 2011-06-21 | Pharmasset, Inc. | Nucleoside phosphoramidate prodrugs |
| JO2778B1 (en) | 2007-10-16 | 2014-03-15 | ايساي انك | Certain Compounds, Compositions and Methods |
| PT3782611T (pt) | 2008-05-15 | 2022-11-18 | Celgene Corp | Formulações orais de análogos da citidina e métodos de utilização dos mesmos |
| US8173621B2 (en) | 2008-06-11 | 2012-05-08 | Gilead Pharmasset Llc | Nucleoside cyclicphosphates |
| US20100055047A1 (en) * | 2008-08-26 | 2010-03-04 | Yiyu Zou | Methods for treating bronchial premalignancy and lung cancer |
| EA019295B1 (ru) | 2008-12-23 | 2014-02-28 | Джилид Фармассет, Ллс. | Соединения пуриновых нуклеозидов и способ их получения |
| US8329666B2 (en) | 2009-04-06 | 2012-12-11 | Eisai Inc. | Compositions and methods for treating cancer |
| US8324180B2 (en) * | 2009-04-06 | 2012-12-04 | Eisai Inc. | Compositions and methods for treating cancer |
| US8329665B2 (en) | 2009-04-06 | 2012-12-11 | Eisai Inc. | Compositions and methods for treating cancer |
| US8609631B2 (en) * | 2009-04-06 | 2013-12-17 | Eisai Inc. | Compositions and methods for treating cancer |
| GB0907551D0 (en) | 2009-05-01 | 2009-06-10 | Univ Dundee | Treatment or prophylaxis of proliferative conditions |
| TWI583692B (zh) | 2009-05-20 | 2017-05-21 | 基利法瑪席特有限責任公司 | 核苷磷醯胺 |
| US8618076B2 (en) | 2009-05-20 | 2013-12-31 | Gilead Pharmasset Llc | Nucleoside phosphoramidates |
| TWI498117B (zh) | 2010-03-31 | 2015-09-01 | Gilead Pharmasset Llc | 核苷氨基磷酸酯 |
| US8563530B2 (en) | 2010-03-31 | 2013-10-22 | Gilead Pharmassel LLC | Purine nucleoside phosphoramidate |
| US8841275B2 (en) | 2010-11-30 | 2014-09-23 | Gilead Pharmasset Llc | 2′-spiro-nucleosides and derivatives thereof useful for treating hepatitis C virus and dengue virus infections |
| DE202012013074U1 (de) | 2011-09-16 | 2014-10-29 | Gilead Pharmasset Lcc | Zusammensetzungen zur Behandlung von HCV |
| US8889159B2 (en) | 2011-11-29 | 2014-11-18 | Gilead Pharmasset Llc | Compositions and methods for treating hepatitis C virus |
| EP2950786B1 (en) | 2013-01-31 | 2019-11-27 | Gilead Pharmasset LLC | Combination formulation of two antiviral compounds |
| JP2016529293A (ja) | 2013-08-27 | 2016-09-23 | ギリアド ファーマセット エルエルシー | ２つの抗ウイルス化合物の組合せ製剤 |
| MY176465A (en) * | 2013-10-29 | 2020-08-11 | Otsuka Pharma Co Ltd | Synthetic route to 2?-deoxy-2?,2?-difluorotetrahydrouridines |
| JP6783224B2 (ja) | 2014-04-04 | 2020-11-11 | デル マー ファーマシューティカルズ | 肺の非小細胞癌腫及び卵巣癌を処置するためのジアンヒドロガラクチトール及びその類縁体又は誘導体の使用 |
| HRP20230265T1 (hr) | 2014-08-22 | 2023-04-14 | Celgene Corporation | Postupci liječenja multiplog mijeloma imunomodulatornim spojevima u kombinaciji s protutijelima |
| EP3960182B1 (en) | 2015-12-03 | 2025-03-19 | EpiDestiny, Inc. | Compositions containing decitabine, 5-azacytidine and tetrahydrouridine and uses thereof |
| WO2017158396A1 (en) | 2016-03-16 | 2017-09-21 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Cytidine deaminase inhibitors for the treatment of pancreatic cancer |
| CA3091027A1 (en) | 2018-02-02 | 2019-08-08 | Maverix Oncology, Inc. | Small molecule drug conjugates of gemcitabine monophosphate |
| CN121324657A (zh) * | 2018-08-28 | 2026-01-13 | 上海宜晟生物科技有限公司 | 测定准确度改善 |
| US11224610B2 (en) * | 2018-09-19 | 2022-01-18 | Otsuka Pharmaceutical Co., Ltd. | Low dose combination CDA substrate drug/cedazuridine with extended administration |
| KR102280330B1 (ko) * | 2018-10-19 | 2021-07-21 | 인터올리고 주식회사 | 치료 효능을 개선한 핵산 변형체 및 이를 포함하는 항암용 약학 조성물 |
| US12448624B2 (en) | 2018-10-19 | 2025-10-21 | Interoligo Corporation | Modified nucleic acid having improved treatment efficacy, and anticancer pharmaceutical composition containing same |
| CN120040527A (zh) | 2019-10-08 | 2025-05-27 | 大塚制药株式会社 | 包括2’-脱氧-2’,2’-二氟四氢尿苷的组合物 |
| ES2992301T3 (es) * | 2020-02-25 | 2024-12-11 | Otsuka Pharma Co Ltd | Formas de dosificación oral sólidas que comprenden decitabina y cedazuridina |
| WO2022204126A1 (en) * | 2021-03-26 | 2022-09-29 | The Cleveland Clinic Foundation | Treatment of rna virus infection with a cytidine deaminase inhibitor |
| US20240279266A1 (en) * | 2021-05-29 | 2024-08-22 | Msn Laboratories Private Limited, R&D Center | An improved process for the preparation of (4r)-1-[(2r,4r,5r)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl) oxolan-2-yl]-4-hydroxy-1,3-diazinan-2one and its intermediate compounds |
| JP2024539267A (ja) | 2021-10-19 | 2024-10-28 | アキラバイオ， インコーポレイテッド | ２’－デオキシシチジンアナログを含む組成物、ならびに鎌状赤血球症、サラセミアおよびがんを処置するためのその使用 |
| US20250127806A1 (en) * | 2021-11-01 | 2025-04-24 | St. John's University | Injectable liquid pharmaceutical composition containing gemcitabine and a cytidine deaminase inhibitor |
| US20230271996A1 (en) * | 2021-12-25 | 2023-08-31 | Scinopharm Taiwan, Ltd. | Process for preparing cedazuridine |
| AU2022476674A1 (en) | 2022-08-31 | 2025-04-17 | Taiho Pharmaceutical Co., Ltd. | Combination therapies for treatment of t-cell lymphomas with tolinapant, cedazuridine and decitabine |
Family Cites Families (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4017606A (en) | 1973-10-04 | 1977-04-12 | The Upjohn Company | Organic compounds and process |
| US4210638A (en) * | 1978-03-17 | 1980-07-01 | Pcr, Inc. | Antiviral composition and method of treating virus diseases |
| US4275057A (en) | 1980-01-28 | 1981-06-23 | The United States Of America As Represented By The Department Of Health, Education And Welfare | Seven-membered ring compounds as inhibitors of cytidine deaminase |
| US4526988A (en) | 1983-03-10 | 1985-07-02 | Eli Lilly And Company | Difluoro antivirals and intermediate therefor |
| DE3481172D1 (de) | 1983-10-26 | 1990-03-08 | Sheldon B Greer | Verfahren und materialien zum empfindlichmachen eines neoplastischen gewebes vor strahlung. |
| DE3587500T2 (de) | 1984-12-04 | 1993-12-16 | Lilly Co Eli | Tumorbehandlung bei Säugetieren. |
| US4965374A (en) | 1987-08-28 | 1990-10-23 | Eli Lilly And Company | Process for and intermediates of 2',2'-difluoronucleosides |
| US5223608A (en) | 1987-08-28 | 1993-06-29 | Eli Lilly And Company | Process for and intermediates of 2',2'-difluoronucleosides |
| US5968914A (en) * | 1987-10-28 | 1999-10-19 | Pro-Neuron, Inc. | Treatment of chemotherapeutic agent and antiviral agent toxicity with acylated pyrimidine nucleosides |
| WO1992018517A1 (en) | 1991-04-17 | 1992-10-29 | Yale University | Method of treating or preventing hepatitis b virus |
| CA2086233C (en) | 1991-04-23 | 1995-10-17 | Wendy Oglevee-O'donovan | In vitro leaf petiole multiplication of pelargoniums |
| FR2682112B1 (fr) | 1991-10-08 | 1993-12-10 | Commissariat A Energie Atomique | Procede de synthese d'acide ribonucleique (arn) utilisant un nouveau reactif de deprotection. |
| US5606048A (en) | 1992-06-22 | 1997-02-25 | Eli Lilly And Company | Stereoselective glycosylation process for preparing 2'-Deoxy-2', 2'-difluoronucleosides and 2'-deoxy-2'-fluoronucleosides |
| US5594124A (en) | 1992-06-22 | 1997-01-14 | Eli Lilly And Company | Stereoselective glycosylation process for preparing 2'-Deoxy-2',2'-difluoropyrimidine nucleosides and 2'-deoxy-2'-fluoropyrimidine nucleosides and intermediates thereof |
| US5821357A (en) | 1992-06-22 | 1998-10-13 | Eli Lilly And Company | Stereoselective glycosylation process for preparing 2'-deoxy-2',2'-difluoropurine and triazole nucleosides |
| US5426183A (en) | 1992-06-22 | 1995-06-20 | Eli Lilly And Company | Catalytic stereoselective glycosylation process for preparing 2'-deoxy-2',2'-difluoronucleosides and 2'-deoxy-2'-fluoronucleosides |
| US5371210A (en) | 1992-06-22 | 1994-12-06 | Eli Lilly And Company | Stereoselective fusion glycosylation process for preparing 2'-deoxy-2',2'-difluoronucleosides and 2'-deoxy-2'-fluoronucleosides |
| EP0641352B1 (en) | 1993-02-23 | 1997-06-04 | City Of Hope | 4-ethoxy 5-fluoro 2'deoxyuridine |
| WO1994026761A1 (en) * | 1993-05-14 | 1994-11-24 | Pro-Neuron, Inc. | Treatment of chemotherapeutic agent and antiviral agent toxicity with acylated pyrimidine nucleosides |
| GB9311252D0 (en) | 1993-06-01 | 1993-07-21 | Hafslund Nycomed As | Cell growth regualtors |
| US5637688A (en) | 1994-12-13 | 1997-06-10 | Eli Lilly And Company | Process for preparing 1-(2'-deoxy-2'-difluoro-d-ribofuranosyl)-4-aminopyrimidin-2-one hydrochloride |
| US5521294A (en) | 1995-01-18 | 1996-05-28 | Eli Lilly And Company | 2,2-difluoro-3-carbamoyl ribose sulfonate compounds and process for the preparation of beta nucleosides |
| AU5300396A (en) * | 1995-03-01 | 1996-09-18 | Human Gene Therapy Research Institute | Radiation enhanced gene therapy for treatment of tumors |
| US6001994A (en) | 1995-12-13 | 1999-12-14 | Eli Lilly And Company | Process for making gemcitabine hydrochloride |
| US5760208A (en) | 1996-08-14 | 1998-06-02 | The Board Of Governors For Higher Education, State Of Rhode Island And Providence Plantations | Process to prepare pyrimidine nucleosides |
| DE60030842T2 (de) | 1999-03-01 | 2007-05-10 | Halogenetics Inc., Aventura | VERWENDUNG VON ZUSAMMENSETZUNGEN ENTHALTEND CldC ALS STRAHLUNGSSENSIBILISATOREN IN DER BEHANDLUNG VON NEOPLASTISCHEN ERKRANKUNGEN |
| US6933287B1 (en) | 1999-03-01 | 2005-08-23 | Sheldon B. Greer | Dramatic simplification of a method to treat neoplastic disease by radiation |
| NZ517437A (en) | 1999-08-26 | 2004-02-27 | Omega Critical Care Ltd | Improvements relating to catheter positioning |
| US6462191B1 (en) | 2000-07-13 | 2002-10-08 | Air Products And Chemicals, Inc. | Synthesis of 2-deoxy-2-fluoro-arabinose derivatives |
| WO2002044194A1 (en) | 2000-11-29 | 2002-06-06 | Mitsui Chemicals, Inc. | L-nucleic acid derivatives and processes for the synthesis thereof |
| EP1353693B1 (en) | 2001-01-16 | 2005-03-16 | Glaxo Group Limited | Pharmaceutical combination containing a 4-quinazolineamine and paclitaxel, carboplatin or vinorelbine for the treatment of cancer |
| EP1387850A2 (en) | 2001-05-18 | 2004-02-11 | Rakesh Kumar | Antiviral nucleosides |
| AU2002322805B2 (en) * | 2001-07-31 | 2007-11-08 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Inhibitor of DNA methylation |
| AU2003217402A1 (en) | 2002-02-14 | 2003-09-04 | Pharmasset Inc | Modified fluorinated nucleoside analogues |
| US6982253B2 (en) | 2002-06-05 | 2006-01-03 | Supergen, Inc. | Liquid formulation of decitabine and use of the same |
| CA2499036A1 (en) | 2002-09-24 | 2004-04-08 | Koronis Pharmaceuticals, Incorporated | 1,3,5-triazines for treatment of viral diseases |
| US7265096B2 (en) | 2002-11-04 | 2007-09-04 | Xenoport, Inc. | Gemcitabine prodrugs, pharmaceutical compositions and uses thereof |
| US8158770B2 (en) | 2004-05-06 | 2012-04-17 | University Of Rochester | Content dependent inhibitors of cytidine deaminases and uses thereof |
| US20060014949A1 (en) | 2004-07-13 | 2006-01-19 | Supergen Inc. | Compositions and formulations of decitabine polymorphs and methods of use thereof |
| EP1812457A1 (en) | 2004-07-30 | 2007-08-01 | Pharmaessentia Corp. | STEREOSELECTIVE SYNTHESIS OF ß-NUCLEOSIDES |
| JP2007522151A (ja) | 2004-12-08 | 2007-08-09 | シコール インコーポレイティド | ジフルオロヌクレオシド及びその調製方法 |
| WO2008085611A2 (en) * | 2006-11-27 | 2008-07-17 | University Of Miami | Designer theraphy of pancreatic tumors |
| WO2009021551A1 (en) | 2007-08-13 | 2009-02-19 | Universite De La Mediterranee | A method for assessing the risk of toxicity in a chemotherapy |
| JO2778B1 (en) | 2007-10-16 | 2014-03-15 | ايساي انك | Certain Compounds, Compositions and Methods |
| WO2010047698A1 (en) | 2008-10-22 | 2010-04-29 | University Of Alabama At Birmingham | Activation-induced cytidine deaminase inhibitor suppression of autoimmune diseases |
| US8324180B2 (en) | 2009-04-06 | 2012-12-04 | Eisai Inc. | Compositions and methods for treating cancer |
| US8329666B2 (en) | 2009-04-06 | 2012-12-11 | Eisai Inc. | Compositions and methods for treating cancer |
| US8329665B2 (en) | 2009-04-06 | 2012-12-11 | Eisai Inc. | Compositions and methods for treating cancer |
| US8609631B2 (en) | 2009-04-06 | 2013-12-17 | Eisai Inc. | Compositions and methods for treating cancer |
-
2008
- 2008-10-14 JO JO2008459A patent/JO2778B1/en active
- 2008-10-15 TW TW097139594A patent/TWI445539B/zh active
- 2008-10-16 BR BRPI0818672A patent/BRPI0818672B8/pt active IP Right Grant
- 2008-10-16 EP EP12151552.2A patent/EP2447272B1/en active Active
- 2008-10-16 EA EA201000642A patent/EA018757B1/ru unknown
- 2008-10-16 PL PL08840633T patent/PL2207786T3/pl unknown
- 2008-10-16 NZ NZ584229A patent/NZ584229A/en unknown
- 2008-10-16 ME MEP-2010-68A patent/ME00997B/me unknown
- 2008-10-16 US US12/252,961 patent/US8268800B2/en active Active
- 2008-10-16 KR KR1020107010621A patent/KR101543049B1/ko active Active
- 2008-10-16 DK DK08840633.5T patent/DK2207786T3/da active
- 2008-10-16 ES ES08840633T patent/ES2384011T3/es active Active
- 2008-10-16 JP JP2010530110A patent/JP5496899B2/ja active Active
- 2008-10-16 WO PCT/US2008/080163 patent/WO2009052287A1/en not_active Ceased
- 2008-10-16 CA CA2702274A patent/CA2702274C/en active Active
- 2008-10-16 UA UAA201003977A patent/UA99476C2/ru unknown
- 2008-10-16 MY MYPI2010001528A patent/MY147970A/en unknown
- 2008-10-16 ES ES12151552.2T patent/ES2616566T3/es active Active
- 2008-10-16 SI SI200830624T patent/SI2207786T1/sl unknown
- 2008-10-16 PT PT08840633T patent/PT2207786E/pt unknown
- 2008-10-16 MX MX2010004109A patent/MX2010004109A/es active IP Right Grant
- 2008-10-16 EP EP08840633A patent/EP2207786B1/en active Active
- 2008-10-16 HR HRP20120419AT patent/HRP20120419T1/hr unknown
- 2008-10-16 RS RS20120232A patent/RS52323B/sr unknown
- 2008-10-16 CN CN2008801117195A patent/CN101827856B/zh active Active
- 2008-10-16 AT AT08840633T patent/ATE548374T1/de active
- 2008-10-18 SA SA08290661A patent/SA08290661B1/ar unknown
-
2010
- 2010-01-26 ZA ZA2010/02178A patent/ZA201002178B/en unknown
- 2010-03-25 IL IL204732A patent/IL204732A/en active IP Right Grant
- 2010-04-09 EC EC2010010095A patent/ECSP10010095A/es unknown
- 2010-04-12 GT GT201000088A patent/GT201000088A/es unknown
- 2010-04-14 NI NI201000055A patent/NI201000055A/es unknown
- 2010-05-12 CR CR11427A patent/CR11427A/es unknown
- 2010-05-13 CO CO10057462A patent/CO6270330A2/es active IP Right Grant
-
2012
- 2012-05-24 CY CY20121100467T patent/CY1112781T1/el unknown
- 2012-07-24 US US13/556,404 patent/US8618075B2/en active Active
-
2013
- 2013-11-25 US US14/088,465 patent/US8951987B2/en active Active
-
2014
- 2014-03-05 JP JP2014043175A patent/JP5859588B2/ja active Active
- 2014-12-29 US US14/584,437 patent/US9567363B2/en active Active
-
2023
- 2023-12-21 HU HUS2300044C patent/HUS2300044I1/hu unknown
- 2023-12-21 NO NO2023047C patent/NO2023047I1/no unknown
- 2023-12-21 NO NO2023048C patent/NO2023048I1/no unknown
- 2023-12-21 HU HUS2300045C patent/HUS2300045I1/hu unknown
- 2023-12-22 CY CY2023028C patent/CY2023028I1/el unknown
- 2023-12-22 FI FIC20230039C patent/FIC20230039I1/fi unknown
- 2023-12-22 FI FIC20230040C patent/FIC20230040I1/fi unknown
- 2023-12-22 CY CY2023029C patent/CY2023029I1/el unknown
- 2023-12-26 FR FR23C1052C patent/FR23C1052I2/fr active Active
- 2023-12-26 FR FR23C1051C patent/FR23C1051I2/fr active Active
- 2023-12-27 NL NL301257C patent/NL301257I2/nl unknown
- 2023-12-27 NL NL301256C patent/NL301256I2/nl unknown
- 2023-12-29 LT LTPA2023539C patent/LTPA2023539I1/lt unknown
- 2023-12-29 LT LTPA2023538C patent/LTC2207786I2/lt unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014177455A5 (enExample) | ||
| CY1125294T1 (el) | Μεθοδοι για την αγωγη μολυνσεων απο ιο arenaviridae | |
| DK3826632T3 (da) | Terapeutiske sammensætninger, der omfatter deutererede eller delvist deutererede n,n-dimethyltryptaminforbindelser | |
| JP2017514910A5 (enExample) | ||
| JP2013518107A5 (enExample) | ||
| EA201791903A1 (ru) | β-D-2'-ДЕЗОКСИ-2'-α-ФТОР-2'-β-C-ЗАМЕЩЕННЫЕ-2-МОДИФИЦИРОВАННЫЕ-N6-ЗАМЕЩЕННЫЕ ПУРИНОВЫЕ НУКЛЕОТИДЫ ДЛЯ ЛЕЧЕНИЯ ВЫЗВАННЫХ HCV ЗАБОЛЕВАНИЙ | |
| JP2011500713A5 (enExample) | ||
| JP2017524735A5 (enExample) | ||
| EA201592075A1 (ru) | Замещенные нуклеозиды, нуклеотиды и их аналоги | |
| MX389802B (es) | Composiciones enriquecidas estereoquimicamente para administracion de acidos nucleicos. | |
| HUE055911T2 (hu) | Citidin-analógokat tartalmazó orális készítmények, és eljárások azok alkalmazására | |
| JP2013032389A5 (enExample) | ||
| JP2016508134A5 (enExample) | ||
| JP2017506627A5 (enExample) | ||
| HK1213018A1 (zh) | 橋接雙環核苷 | |
| UA99476C2 (en) | 2'-fluoro-2'-deoxytetrahydrouridines as cytidine deaminase inhibitors | |
| JP2014507446A5 (enExample) | ||
| LT3512863T (lt) | 2'-pakeistieji-n6-pakeistieji purino nukleotidai, skirti gydymui rnr virusu | |
| JP2016540015A5 (enExample) | ||
| EP3384911A4 (en) | PHARMACEUTICAL COMPOSITION COMPRISING 2 - {[4- (N-5,6-DIPHENYLPYRAZIN-2-YL)] - N-ISOPROPYLAMINO} BUTYLOXY-N- (METHYLSULFONYL) ACETAMIDE | |
| CN109863160A (zh) | 核苷磷酸类化合物及其制备方法和用途 | |
| JP2011518153A5 (enExample) | ||
| PH12015502589A1 (en) | 4`-azido, 3`-deoxy-3`-fluoro substituted nucleoside derivatives | |
| JP2016540019A5 (enExample) | ||
| MA40781A (fr) | Composition pharmaceutique d'isotrétinoïne à faible dosage destinée à la voie orale |